Modality
Multispecific
MOA
AHRant
Target
JAK2
Pathway
Apoptosis
Ovarian CaUrothelial Ca
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
→ Jun 2028
Phase 2Current
NCT06085736
2,767 pts·Urothelial Ca
2019-12→2028-06·Not yet recruiting
NCT06482862
2,589 pts·Ovarian Ca
2017-02→2026-09·Active
5,356 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-015mo awayPh3 Readout· Ovarian Ca
2028-06-082.2y awayPh3 Readout· Urothelial Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Active
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-09-01 · 5mo away
Ovarian Ca
Ph3 Readout
2028-06-08 · 2.2y away
Urothelial Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06085736 | Phase 2/3 | Urothelial Ca | Not yet recr... | 2767 | EASI-75 |
| NCT06482862 | Phase 2/3 | Ovarian Ca | Active | 2589 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 |